RAPP

Rapport Therapeutics' stock has experienced significant movement over the past six months. The stock price increased by 274.93% over the last 12 months, with a year-to-date return of 31.61% and an 18.52% increase in the past month as of May 8, 2026. Key events impacting the stock include the Q1 2026 earnings report where the company reported its first collaboration revenue of $20.0 million, significantly beating revenue expectations, driven by the licensing deal with Tenacia Biotechnology. Positive Phase 2a follow-up data for RAP-219 in focal onset seizures demonstrated sustained seizure reduction and a longer half-life. Insider selling by Third Rock Ventures tempered sentiment despite positive news. Raymond James initiated coverage with a 'Strong Buy' rating, contributing to positive investor sentiment. A $269.4 million follow-on equity offering completed in 2025 bolstered the company's cash reserves, providing funding for late-stage trials.